Kim JS, et al. - Researchers examined the anti-proliferative effects of metformin (MET)+simvastatin (SIM) vs each agent alone in endometrial cancer cells. On treating RL95-2, HEC1B, and Ishikawa endometrial cancer cell lines with MET and/or SIM, they determined growth inhibition by MTS cell proliferation assays. Outcomes suggest that inhibition of endometrial cancer cell viability following MET+SIM treatment was synergistic. Apoptosis and mTOR pathway inhibition may have a mediatory role in this. Results thereby provide preclinical evidence supporting further clinical investigation of the combination of these well-tolerated drugs for endometrial cancer treatment.